RNAConnect, a life science company providing next generation tools to the RNA community, today announced the commercial availability of the UltraMarathonRT® Direct RNA‑Seq (uMRT DRS) Kit, a native‑RNA ...

(RTTNews) - TransCode Therapeutics, Inc. (RNAZ), a clinical-stage oncology company focused on RNA therapeutics, announced on Wednesday that it has entered into a securities purchase agreement to raise ...

BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported ...

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its ...

An innovative three-color method for capturing images of mRNA inside live mammalian cells has been developed by UMass Amherst chemists. Because RNA is both incredibly important to human life and ...

An innovative three-color method for capturing images of mRNA inside live mammalian cells has been developed by UMass Amherst chemists. Because RNA is both incredibly important to human life and ...

BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to more effectively treating ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap RNA oncology company with a market capitalization of $6.22 ...

TransCode Therapeutics RNAZ reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at ...